The Office of the Comptroller of the Currency (OCC) plans to announce the final rules regarding stablecoin payments before November. This signal was given by Jonathan Gould during the Wyoming Blockchain Symposium on August 19. Gould stated that the agency aims to expedite the release of the final version of the regulation and begin processing applications in the new year. A report released by the OCC indicates that the agency is focused on adhering to this timeline. The GENIUS Act, signed in July 2025, established a federal framework for payment stablecoins, with a statutory deadline for federal agencies to complete the rules by July; however, the OCC has yet to issue the final rules. In February, the OCC released a 376-page proposal concerning its authority on the matter, along with capital and liquidity requirements related to risk management, posing over 200 questions that were open for public comment until May 1. The materials discussed reserve requirements, compliance behaviors, and capital standards similar to those of banks, applicable to both licensed banks and non-bank applicants. Gould mentioned that the final version will be published after analyzing industry feedback. Other regulatory bodies are also advancing coordinated proposals, with the Treasury Department issuing a notice on August 17 regarding the proposed rulemaking for the implementation of Section 3 of the GENIUS Act and initiating public comments.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.
